SMN1 and metabolic dysfunction-associated steatotic liver disease: SMA1 and 2 patients are more likely to develop dyslipidemia, and nonalcoholic fatty liver disease (NAFLD) has also been experimentally reproduced in mouse models, since this increased susceptibility has occurred with an incidence of even 37% [80].